Search / Trial NCT06614595

Transfusion in Lower Risk MDS Patients: Predictors of Adequacy of Transfusion and Quality of Life in Lower Risk MDS

Launched by FUNDACIÓN PARA LA INVESTIGACIÓN BIOSANITARIA DEL PRINCIPADO DE ASTURIAS · Sep 24, 2024

Apply for Trial

Trial Information

Current as of October 03, 2024

Recruiting

Keywords

Myelodysplastic Syndromes Red Blood Cell Transfusion Quality Of Life

Description

At inclusion and before red blood cell (rbc) transfusion, patients cardiorespiratory function will be evaluated with an ergospirometer Likewise, before and after rbc transfusion, patients will be asked to complete the QUALMS, a QoL instrument which will be supplied by Dr. Gregory Abel at Dana-Farber in the U.S., who led its development team. Before and after rbc transfusion, hemoglobin, pretrasfusional hemoglobin, pre and post cardiac biomarkers troponin and NTproBNP will be collect.Pre and post serum and plasma will also be collected for cytokine analysis.

Gender

ALL

Eligibility criteria

  • Subjects must meet all of the following inclusion criteria:
  • 1. They must be able to understand the study procedures, comply with them, and consent in writing prior to any specific study procedure.
  • 2. Must be able to understand the study procedures, comply with them, and give written informed consent prior to any study-specific procedure.
  • 3. Adult subjects ≥ 18 years of age with a diagnosis of myelodysplastic syndrome.
  • 4. Very low, low or intermediate IPSS-R risk category.
  • 5. Subject requires are red blood cell transfusion dependent with the following criteria: requires an average of 2 to 6 units of CH on average over an 8-week period.
  • 6. ECOG 0-3.
  • Exclusion criteria
  • 1. Subject undergoing any of the following treatments: azacitidine, decitabine, venetoclax, cytotoxic chemotherapy, radiotherapy, arsenic trioxide, interferon or interleukin.
  • 2. High or very high IPSS-R risk category.
  • 3. Subject diagnosed with any active neoplasm except:
  • * epidermoid or basal cell carcinoma,
  • * carcinoma in situ of the uterine cervix
  • * Carcinoma in situ of the breast
  • 4. Subjects with a score on the New York Heart Association Scale IV.
  • 5. Subjects with major surgery within 8 weeks prior to study inclusion. Subjects must have fully recovered from any previous surgery prior to inclusion in the study.
  • 6. Subject with known clinically significant anaemia due to iron, vitamin B12 or folate deficiencies or autoimmune or hereditary haemolytic anaemia or uncontrolled hypothyroidism or known clinically significant haemorrhage or sequestration or subject with drug induced anaemia.
  • 7. New onset or uncontrolled seizures.
  • 8. Subjects with uncontrolled systemic fungal, bacterial or viral infections (defined as ongoing signs or symptoms related to the infection without improvement despite appropriate antibiotics or antimicrobial therapy).
  • 9. Pregnant or breastfeeding women.
  • 10. The subject has any condition, including the presence of laboratory abnormalities that would place the subject at unacceptable risk if he/she were to participate in the study.
  • 11. The subject has any condition or receives concomitant medication that confounds the ability to interpret the study data.

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Oviedo, Asturias, Spain

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0